



# Associations of Plasma Concentrations of Dichlorodiphenyldichloroethylene and Polychlorinated Biphenyls with Prostate Cancer: A Case–Control Study in Guadeloupe (French West Indies)

Elise Emeville, Arnaud Giusti, Xavier Coumoul, Jean-Pierre Thome, Pascal  
Blanchet, Luc Multigner

## ► To cite this version:

Elise Emeville, Arnaud Giusti, Xavier Coumoul, Jean-Pierre Thome, Pascal Blanchet, et al.. Associations of Plasma Concentrations of Dichlorodiphenyldichloroethylene and Polychlorinated Biphenyls with Prostate Cancer: A Case–Control Study in Guadeloupe (French West Indies). *Environmental Health Perspectives*, 2015, 123 (4), pp.317-323. 10.1289/ehp.1408407 . hal-02195806

**HAL Id: hal-02195806**

**<https://univ-rennes.hal.science/hal-02195806>**

Submitted on 26 Jul 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Associations of Plasma Concentrations of Dichlorodiphenyldichloroethylene and Polychlorinated Biphenyls with Prostate Cancer: A Case–Control Study in Guadeloupe (French West Indies)

Elise Emeville,<sup>1,2</sup> Arnaud Giusti,<sup>3</sup> Xavier Coumoul,<sup>4,5</sup> Jean-Pierre Thomé,<sup>3</sup> Pascal Blanchet,<sup>1,6</sup> and Luc Multigner<sup>1,2</sup>

<sup>1</sup>Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1085, IRSET, Pointe à Pitre, Guadeloupe, France; <sup>2</sup>Université de Rennes 1, Rennes, France; <sup>3</sup>Center for Analytical Research and Technology, Liege University, Liege, Belgium; <sup>4</sup>INSERM, UMR-S 747, Toxicologie Pharmacologie et Signalisation Cellulaire, Paris, France; <sup>5</sup>Université Paris Descartes, Sorbonne Paris Cité, Paris, France; <sup>6</sup>Service d'Urologie, Centre Hospitalier Universitaire Guadeloupe, Abymes, Guadeloupe, France

**BACKGROUND:** Long-term exposure to persistent pollutants with hormonal properties (endocrine-disrupting chemicals; EDCs) may contribute to the risk of prostate cancer (PCa). However, epidemiological evidence remains limited.

**OBJECTIVES:** We investigated the relationship between PCa and plasma concentrations of universally widespread pollutants, in particular *p,p'*-dichlorodiphenyl dichloroethene (DDE) and the non-dioxin-like polychlorinated biphenyl congener 153 (PCB-153).

**METHODS:** We evaluated 576 men with newly diagnosed PCa (before treatment) and 655 controls in Guadeloupe (French West Indies). Exposure was analyzed according to case–control status. Associations were assessed by unconditional logistic regression analysis, controlling for confounding factors. Missing data were handled by multiple imputation.

**RESULTS:** We estimated a significant positive association between DDE and PCa [adjusted odds ratio (OR) = 1.53; 95% CI: 1.02, 2.30 for the highest vs. lowest quintile of exposure;  $p_{\text{trend}} = 0.01$ ]. PCB-153 was inversely associated with PCa (OR = 0.30; 95% CI: 0.19, 0.47 for the highest vs. lowest quintile of exposure values;  $p_{\text{trend}} < 0.001$ ). Also, PCB-153 was more strongly associated with low-grade than with high-grade PCa.

**CONCLUSIONS:** Associations of PCa with DDE and PCB-153 were in opposite directions. This may reflect differences in the mechanisms of action of these EDCs; and although our findings need to be replicated in other populations, they are consistent with complex effects of EDCs on human health.

**CITATION:** Emeville E, Giusti A, Coumoul X, Thomé JP, Blanchet P, Multigner L. 2015. Associations of plasma concentrations of dichlorodiphenyldichloroethylene and polychlorinated biphenyls with prostate cancer: a case–control study in Guadeloupe (French West Indies). *Environ Health Perspect* 123:317–323; <http://dx.doi.org/10.1289/ehp.1408407>

## Introduction

Prostate cancer (PCa) is the second most common noncutaneous cancer among men worldwide and the leading noncutaneous cancer among men in developed countries (Center et al. 2012). Little is known about the risk factors associated with this cancer: Advancing age, ethnic origins, and a family history of PCa are the only established risk factors (Damber and Aus 2008; Hsing and Chokkalingam 2006). Many lifestyle-related risk factors, including westernization of eating habits and environmental chemical pollution, have been implicated, but their true roles in the etiology of PCa remain unclear (Damber and Aus 2008; Hsing and Chokkalingam 2006).

The effects of exposure to synthetic chemicals with hormonal properties in the environment, also called endocrine disruptors (EDCs), on prostate cancer development are also matters of debate (Diamanti-Kandarakis et al. 2009; Prins 2008; World Health Organization 2013). Models of PCa are not available for regulatory testing. This makes the identification of prostatic hormonal carcinogens very difficult, and forces researchers to rely on epidemiological studies. However, epidemiological evidence remains limited (Soto and Sonnenschein 2010).

Persistent organic pollutants, including *p,p'*-dichlorodiphenyldichloroethylene (DDE, the major and most stable metabolite of dichlorodiphenyltrichloroethane, DDT) and polychlorinated biphenyls (PCBs), have attracted attention because of their widespread presence both in the environment and in human beings, and their ability to interfere with hormone-regulated processes (Kelce et al. 1995; Plísková et al. 2005). Several epidemiological studies have investigated relationships between human exposure to DDE and PCBs, determined by blood measurement, and PCa, but most of them found no association (Aronson et al. 2010; Ritchie et al. 2003, 2005; Sawada et al. 2010). One study in the United States that included 65 PCa cases and 1,920 noncases reported a positive but not significant association with prevalent prostate cancer risk (Xu et al. 2010).

In a population-based case–control study of incident PCa patients and control subjects in the general population in Guadeloupe (French West Indies), environmental exposure to the estrogenic insecticide chlordecone was positively associated with PCa (Multigner et al. 2010). Here we report continuation of this study with a more detailed investigation of associations of DDE and PCBs with PCa.

## Methods

**Study population.** This study took place in Guadeloupe (French West Indies), a Caribbean archipelago, where most of the inhabitants are of African descent. The study included 709 consecutive incident cases of histologically confirmed PCa and 723 controls without PCa. Details of the selection of cases and controls have been described elsewhere (Multigner et al. 2010). Briefly, cases were recruited among subjects attending public and private urology clinics, with a recruitment area covering the entire territory of the Guadeloupe Archipelago. Controls were recruited from men participating in a free systematic health screening program open to the general population: Each year, a random population sample selected in accordance with the sex and age distribution of the general population was invited to participate in the program. Consecutive men  $\geq 45$  years of age were then invited to participate as controls in our case–control study of PCa, with selection according to the approximate age distribution of PCa diagnosis in Guadeloupe. Inclusion criteria for both cases and controls were current residence in Guadeloupe, both parents born on any Caribbean island with a population of predominantly African descent, and no hormone treatments or use of any other drugs known to influence the hypothalamic–pituitary–gonadal–adrenal axis (including inhibitors of 5 $\alpha$ -reductase). Additional inclusion criteria for controls were normal findings upon digital rectal examination and total plasma PSA (prostate-specific antigen)

Address correspondence to L. Multigner, Inserm U1085–IRSET, Faculté de Médecine, Campus de Fouillole, BP145, 97154 Pointe à Pitre Cedex, Guadeloupe, French West Indies. Telephone: 590 690 71 96 07. E-mail: [luc.multigner@inserm.fr](mailto:luc.multigner@inserm.fr)

Supplemental Material is available online (<http://dx.doi.org/10.1289/ehp.1408407>).

This work was supported by the French National Health Directorate. E.E. is supported by a Ph.D. fellowship from the Ligue Nationale Contre le Cancer.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors declare they have no actual or potential competing financial interests.

Received: 12 March 2014; Accepted: 19 November 2014; Advance Publication: 21 November 2014; Final Publication: 1 April 2015.

concentration no higher than the 75th percentile for the corresponding age group of African-American men without clinical evidence of PCa (Morgan et al. 1996). Trained nurses obtained information for both patients and controls. Case patients were interviewed within 2 months of diagnosis, before receiving any kind of treatment. All subjects were interviewed in person to obtain information about their age (years), Caribbean origin (French West Indies, Haiti, or Dominica), education (primary, secondary, high school and higher), weight and height allowing the calculation of body mass index (BMI; kilograms per meter squared), waist and hip circumference allowing the calculation of waist-to-hip ratio ( $\leq 0.95$ ,  $> 0.95$ ), smoking (never, former, or current), alcohol consumption (never, former, or current), diabetes type 2 (no, yes), past residence in Western countries (no, yes), history of PSA screening (within the preceding 5 years: no, yes), and family history of PCa (first degree relatives: no, yes, not known). Participants were also asked to provide a blood sample between 0800 and 1000 hours, after overnight fasting. The study was approved by the Guadeloupean ethics committee for studies involving human subjects. Each participant provided written informed consent.

**Laboratory assays.** A high-resolution gas chromatograph (Thermo Quest Trace 2000, Milan, Italy) equipped with a Ni63 electron capture detection system was used to determine the serum concentrations of 24 PCB congeners (International Union of Pure and Applied Chemistry number): 6 dioxin-like (77, 105, 118, 126, 156, and 169) and 18 non-dioxin-like (18, 28, 52, 101, 110, 128, 138, 143, 149, 153, 170, 180, 183, 187, 194, 195, 206, and 209); *p,p'*-DDT, *p,p'*-DDD (dichlorodiphenyldichloroethane), and *p,p'*-DDE; the  $\alpha$ ,  $\beta$ , and  $\gamma$  isomers of hexachlorocyclohexane (HCH); and chlordecone. The limit of detection (LOD) was 0.05  $\mu\text{g/L}$  for all organochlorine compounds except for chlordecone (0.06  $\mu\text{g/L}$ ). Detailed information about sampling, analysis, and quality assurance and control has been provided elsewhere (Debie et al. 2003; Multigner et al. 2010). Plasma total cholesterol and total triglyceride concentrations were determined enzymatically (DiaSys Diagnostic Systems GmbH, Holzheim, Germany), and total lipid concentration was calculated as previously described (Bernert et al. 2007).

**Statistical analysis.** We restricted our analysis to chemicals detected at a rate of more than 80% (DDE; PCB congeners 138, 153, and 180; and chlordecone) (Table 1).

Correlations between concentrations of the frequently detected pollutants were explored by Spearman's rank correlation analysis (see Supplemental Material, Table S1). The concentrations of the various PCBs were highly correlated (Spearman's  $\rho \geq 0.76$ ; all *p*-values  $< 0.001$ ), so we restricted further analysis to PCB-153.

The odds ratio (OR) and 95% confidence intervals (CIs) for the association between PCa and organochlorines according to category of exposure were estimated using unconditional logistic regression. Organochlorines were categorized into quintiles according to the distribution in control subjects. Exposure levels equal to or below the LOD were included in the first (lowest) quintile.

Potential confounders were included as covariates in logistic models if they predicted case status (Table 2) and exposure (see Supplemental Material, Table S2) with *p*  $< 0.05$ . We also adjusted all models for total lipids (grams per liter), rather than modeling concentrations of the fat-soluble exposure of interest on a per-unit serum-lipid basis, because the latter approach may be prone to bias (Porta et al. 2009). For each exposure, we also considered the other contaminants as potential confounders. Spearman's rank correlation coefficients between chlordecone and DDE concentrations and between chlordecone and PCB-153 concentrations were low ( $\rho = 0.05$  and  $0.07$  in controls, and  $0.04$  and  $0.07$  in cases, respectively; see Supplemental Material, Table S1). Consequently, chlordecone was not considered as a confounder.

Next, models of DDE as the primary exposure were adjusted for age (log linearity of age was not achieved, so age was categorized as quartiles according to the age distribution of the controls), waist-to-hip ratio, type 2 diabetes, alcohol consumption, total lipids, and PCB-153 (quintiles). Models of PCB-153 as the exposure were adjusted for the same covariates, plus Caribbean origin and past residence in a Western country, and DDE (quintiles). Sensitivity analyses were conducted including additional adjustment for BMI, PSA screening history, family history of PCa, and chlordecone. Additional sensitivity analyses were realized excluding any subject ( $n = 199$ ), control or case, with a prediagnostic BMI  $< 18.5$  or  $> 30$ .

Missing data for covariates varied from none to 2 (0.2%) for past residence in Western countries and for PSA screening history, 8 (0.6%) for smoking, 20 (1.6%) for alcohol, 27 (2.2%) for family history of PCa, 30 (2.4%) for education, 34 (2.8%) for diabetes, 37 (3.0%) for BMI, and 219 (17.8%) for waist-to-hip ratio. Missing data were handled by multiple imputations

**Table 1.** Detection and concentrations of organochlorine pollutants in plasma samples from the study population [ $\mu\text{g/L}$  ( $\mu\text{g/g}$  lipids)].

| Organochlorine <sup>a</sup> | Detection frequency (%) | Percentile  |             |              |              | Maximum     |
|-----------------------------|-------------------------|-------------|-------------|--------------|--------------|-------------|
|                             |                         | 10th        | 25th        | 50th         | 75th         |             |
| Controls                    |                         |             |             |              |              |             |
| <i>p,p'</i> -DDT            | 36.2                    | < LOD       | < LOD       | < LOD        | 0.07 (0.01)  | 1.7 (0.32)  |
| <i>p,p'</i> -DDD            | 24.0                    | < LOD       | < LOD       | < LOD        | 0.04 (0.008) | 0.84 (0.15) |
| <i>p,p'</i> -DDE            | 96.2                    | 0.39 (0.07) | 0.98 (0.18) | 2.06 (0.38)  | 4.37 (0.75)  | 27.8 (6.7)  |
| PCB-28                      | 54.5                    | < LOD       | < LOD       | 0.07 (0.01)  | 0.28 (0.05)  | 8.0 (1.4)   |
| PCB-52                      | 42.6                    | < LOD       | < LOD       | < LOD        | 0.28 (0.05)  | 12.7 (2.5)  |
| PCB-101                     | 52.1                    | < LOD       | < LOD       | 0.05 (0.009) | 0.13 (0.02)  | 1.1 (0.21)  |
| PCB-118                     | 59.2                    | < LOD       | < LOD       | 0.08 (0.01)  | 0.20 (0.03)  | 3.3 (0.9)   |
| PCB-138                     | 97.4                    | 0.18 (0.03) | 0.31 (0.06) | 0.53 (0.10)  | 0.90 (0.16)  | 12.2 (2.4)  |
| PCB-153                     | 98.2                    | 0.24 (0.05) | 0.48 (0.09) | 0.85 (0.15)  | 1.47 (0.26)  | 16.5 (3.5)  |
| PCB-180                     | 97.4                    | 0.23 (0.04) | 0.39 (0.07) | 0.64 (0.12)  | 1.03 (0.18)  | 10.3 (2.0)  |
| $\alpha$ -HCH               | 35.9                    | < LOD       | < LOD       | < LOD        | 0.08 (0.01)  | 1.6 (0.32)  |
| $\beta$ -HCH                | 43.5                    | < LOD       | < LOD       | < LOD        | 0.09 (0.02)  | 1.9 (0.30)  |
| $\gamma$ -HCH               | 27.7                    | < LOD       | < LOD       | < LOD        | 0.08 (0.01)  | 1.8 (0.41)  |
| Chlordecone                 | 84.1                    | < LOD       | 0.17 (0.03) | 0.42 (0.08)  | 0.83 (0.15)  | 49.2 (8.8)  |
| Cases                       |                         |             |             |              |              |             |
| <i>p,p'</i> -DDT            | 29.3                    | < LOD       | < LOD       | < LOD        | 0.06 (0.01)  | 2.5 (0.43)  |
| <i>p,p'</i> -DDD            | 20.1                    | < LOD       | < LOD       | < LOD        | 0.03 (0.006) | 0.99 (0.15) |
| <i>p,p'</i> -DDE            | 95.5                    | 0.40 (0.08) | 1.11 (0.22) | 2.55 (0.50)  | 5.74 (1.07)  | 40.1 (6.6)  |
| PCB-28                      | 52.6                    | < LOD       | < LOD       | 0.06 (0.01)  | 0.29 (0.05)  | 6.8 (1.1)   |
| PCB-52                      | 49.3                    | < LOD       | < LOD       | < LOD        | 0.38 (0.07)  | 6.7 (1.1)   |
| PCB-101                     | 51.2                    | < LOD       | < LOD       | 0.05 (0.009) | 0.13 (0.02)  | 1.2 (0.17)  |
| PCB-118                     | 62.0                    | < LOD       | < LOD       | 0.08 (0.02)  | 0.18 (0.03)  | 2.4 (0.52)  |
| PCB-138                     | 97.9                    | 0.17 (0.03) | 0.30 (0.06) | 0.54 (0.10)  | 0.87 (0.18)  | 6.7 (1.1)   |
| PCB-153                     | 98.8                    | 0.23 (0.04) | 0.41 (0.06) | 0.78 (0.10)  | 1.24 (0.18)  | 8.4 (1.3)   |
| PCB-180                     | 97.2                    | 0.25 (0.05) | 0.37 (0.07) | 0.62 (0.12)  | 0.90 (0.18)  | 6.2 (1.0)   |
| $\alpha$ -HCH               | 28.5                    | < LOD       | < LOD       | < LOD        | 0.05 (0.01)  | 1.2 (0.20)  |
| $\beta$ -HCH                | 38.0                    | < LOD       | < LOD       | < LOD        | 0.11 (0.02)  | 2.2 (0.46)  |
| $\gamma$ -HCH               | 18.4                    | < LOD       | < LOD       | < LOD        | < LOD        | 0.65 (0.13) |
| Chlordecone                 | 82.8                    | < LOD       | 0.18 (0.03) | 0.43 (0.08)  | 0.94 (0.18)  | 26.4 (4.1)  |

<sup>a</sup>PCB congeners 18, 77, 101, 105, 110, 126, 128, 143, 149, 156, 169, 170, 183, 187, 194, 195, 206, and 209 were below the LOD in all cases and controls.

according to the methodology described by Rubin (1987) and Little and Rubin (1987) using chained equations (MICE; multiple imputation by chained equations) (Van Buuren et al. 1999; White et al. 2009). For the imputation procedure, we included the following characteristics: age, Caribbean origin, education, weight, height, waist and hip circumference, smoking, alcohol, diabetes, PSA screening history, family history of PCa, past residence in Western countries, total plasma lipids, all organochlorines, and case-control status. Five imputed data sets were generated using 20 cycles per imputation, and the main analyses were repeated using the imputed data. In addition, we performed sensitivity analyses substituting missing data with a missing value indicator variable, and by using complete case analyses restricted to participants with known values of all covariates. Tests for trends were performed by modeling categorical exposures as ordinal variables after assigning median values to each exposure category.

We considered possible interactions between organochlorine exposure and covariates in relation to PCa. The cross-product of covariates (BMI < 25 or > 25 kg/m<sup>2</sup>; waist-to-hip ratio ≤ 0.95 or > 0.95; smoking, never versus former or current; alcohol consumption, never versus former or current; diabetes type 2, yes, no; past residence in Western countries, yes, no; history of PSA screening, yes, no) and exposures (quintiles) was introduced in the logistic model. Subjects with missing values for the factors of interest were excluded from these analyses. We adjusted for the same covariates as the main model for each exposure. Consistent with the recommendations of Seaman et al. (2012), these analyses were restricted to participants with known values of all covariates. The *p*-value for interaction was calculated by the likelihood ratio test comparing the log-likelihood for the model with the interaction terms to the log-likelihood for the model without the interaction term. Interactions with a *p*-value for the cross-term product ≤ 0.20 were further assessed with stratified analyses.

Polytomous logistic regressions models were used to estimate associations between exposures and case subgroups (versus controls) according to grade (low grade: Gleason score < 7 or 3 + 4; high grade: Gleason score 4 + 3 or > 7) and clinical stage at diagnosis (tumor, nodes, metastases; localized stage: T1c or T2 and N0 and M0; advanced stage: T3 or T4, or N+ or M+). Exposures were categorized into tertiles according to the distribution in control subjects for these analyses.

Using previously published data (Multigner et al. 2010), we reanalyzed the association between chlordecone exposure and PCa among participants included in

the present analysis, with additional adjustment for plasma DDE and PCB-153. After analysis of quality control samples consisting of human plasma spiked with a series of concentrations of chlordecone, we defined the LOD for plasma chlordecone concentrations as 0.06 µg/L, rather than using an LOD of 0.25 µg/L, as in our previous analysis (Multigner et al. 2010).

SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA) was used for analyses; all tests were two-sided, and *p*-values < 0.05 were considered statistically significant.

## Results

The results presented here were obtained from a study population comprising 576 of the 709 eligible PCa cases and 655 of the eligible 722 controls, from whom we were able to obtain blood samples and measure plasma organochlorine concentrations. The baseline characteristics of the study population are summarized in Table 2.

The adjusted OR was 1.53 (95% CI: 1.02, 2.30) for men in the highest quintile of DDE concentration compared with men in the lowest quintile (Table 3). The relationship

**Table 2.** Baseline characteristics of the study population.

| Characteristic                       | Cases<br>[no. (%)] | Controls<br>[no. (%)] | <i>p</i> -Value <sup>a</sup> |
|--------------------------------------|--------------------|-----------------------|------------------------------|
| Age (years) [mean (range)]           | 65.9 (52.6–79.1)   | 60.9 (48.0–77.1)      | < 0.001                      |
| Caribbean origin                     |                    |                       |                              |
| French West Indies                   | 556 (96.5)         | 598 (91.3)            | < 0.001                      |
| Haiti or Dominica                    | 20 (3.5)           | 57 (8.7)              |                              |
| Education                            |                    |                       |                              |
| Primary                              | 349 (61.0)         | 362 (57.5)            | 0.04                         |
| Secondary                            | 147 (25.7)         | 201 (32.0)            |                              |
| High school and higher               | 76 (13.3)          | 66 (10.5)             |                              |
| Missing data                         | 4                  | 26                    |                              |
| Body mass index (kg/m <sup>2</sup> ) |                    |                       |                              |
| < 25                                 | 241 (44.5)         | 306 (46.9)            | 0.54                         |
| 25 to < 30                           | 240 (44.3)         | 268 (41.1)            |                              |
| ≥ 30                                 | 61 (11.2)          | 78 (12.0)             |                              |
| Missing data                         | 34                 | 3                     |                              |
| Waist-to-hip ratio                   |                    |                       |                              |
| ≤ 0.95                               | 196 (54.4)         | 455 (69.8)            | < 0.001                      |
| > 0.95                               | 164 (45.6)         | 197 (30.2)            |                              |
| Missing data                         | 216                | 3                     |                              |
| Smoking                              |                    |                       |                              |
| Never                                | 355 (62.2)         | 410 (62.9)            | 0.80                         |
| Former or current                    | 216 (37.8)         | 242 (37.1)            |                              |
| Missing data                         | 5                  | 3                     |                              |
| Alcohol consumption                  |                    |                       |                              |
| Never                                | 74 (13.0)          | 112 (17.4)            | 0.03                         |
| Former or current                    | 494 (87.0)         | 536 (82.6)            |                              |
| Missing data                         | 8                  | 12                    |                              |
| Type 2 diabetes                      |                    |                       |                              |
| No                                   | 457 (81.5)         | 556 (87.4)            | 0.004                        |
| Yes                                  | 104 (18.5)         | 80 (12.6)             |                              |
| Missing data                         | 15                 | 19                    |                              |
| Past residence in Western countries  |                    |                       |                              |
| No                                   | 403 (70.0)         | 498 (76.3)            | 0.01                         |
| Yes                                  | 173 (30.0)         | 155 (23.7)            |                              |
| Missing data                         | —                  | 2                     |                              |
| PSA screening history                |                    |                       |                              |
| No                                   | 278 (48.4)         | 572 (87.3)            | < 0.001                      |
| Yes                                  | 296 (51.6)         | 83 (12.7)             |                              |
| Missing data                         | 2                  | —                     |                              |
| Family history of prostate cancer    |                    |                       |                              |
| No                                   | 317 (55.9)         | 498 (78.2)            | < 0.001                      |
| Yes                                  | 144 (25.4)         | 66 (10.4)             |                              |
| Do not know                          | 106 (18.6)         | 74 (11.4)             |                              |
| Missing data                         | 9                  | 18                    |                              |
| Gleason score                        |                    |                       |                              |
| < 7 or 3 + 4                         | 462 (82.1)         | —                     | —                            |
| > 7 or 4 + 3                         | 101 (17.9)         | —                     |                              |
| Missing data                         | 9                  | —                     |                              |
| Clinical stage (T, N, M)             |                    |                       |                              |
| T1c or T2 and N0 and M0              | 485 (87.4)         | —                     | —                            |
| T3 or T4, or N+ or M+                | 70 (12.6)          | —                     |                              |
| Missing data                         | 21                 | —                     |                              |

<sup>a</sup>*p*-Values were calculated using a two-sided chi-square test for a comparison of percentages or by a two-sided Student *t*-test for a comparison of means.



between exposure and PCa was significant ( $p_{\text{trend}} = 0.01$ ). This overall trend seems to be mainly driven by the OR for the highest versus lowest quintiles, because the other ORs were close to null. Results of sensitivity analyses were comparable with the primary analysis when missing data were modeled using missing value indicator categories; when we performed complete case analyses; and when BMI, PSA screening history, family history of PCa, or chlordecone exposure were included in the full model (see Supplemental Material, Table S3). Excluding subjects with BMI < 18.5 and > 30 resulted in a slight decrease in the OR (1.43; 95% CI: 0.93, 2.20), but the trend across exposure categories remained significant ( $p_{\text{trend}} = 0.04$ ) (see Supplemental Material, Table S3).

Contrary to what was observed for DDE, adjusted ORs relative to the lowest quintile of PCB-153 concentration all were significantly below 1 (OR = 0.30; 95% CI: 0.19, 0.47 for the highest versus lowest quintile) (Table 3). The overall trend for the association across exposure categories was significant ( $p_{\text{trend}} < 0.001$ ). In sensitivity analyses, associations were comparable when missing data were modeled using missing value indicator categories; when restricted to a complete

case analysis; and when additionally adjusted for BMI, PSA screening history, family history of PCa, or chlordecone exposure (see Supplemental Material, Table S4). Also, exclusion of subjects with BMI < 18.5 and > 30 did not greatly affect the ORs (see Supplemental Material, Table S4).

We did not find any evidence of effect modification (interaction  $p$ -values > 0.2, data not shown) except for family history of PCa and PCB-153 exposure (see Supplemental Material, Table S5). Associations between PCB-153 exposure and PCa were stronger in men without a family history of PCa, and the interaction terms, although not significant, were < 0.10 for the three highest quintiles of exposure.

Our next analyses considered clinical characteristics. The adjusted OR for cases with high-grade Gleason score was 1.92 (95% CI: 1.04, 3.54) for men in the highest tertile relative to men in the lowest tertile of DDE concentration (Table 4), but this was not significantly different from the corresponding OR value for cases with low-grade Gleason score ( $p_{\text{heterogeneity}} = 0.13$ ). For PCB-153, a significant inverse association was observed among cases with low-grade Gleason score (OR = 0.35; 95% CI: 0.25, 0.51) for men

in the highest tertile relative to men in the lowest tertile (Table 4); this was significantly different from what was observed for cases with high-grade score ( $p_{\text{heterogeneity}} = 0.04$ ). No significant differences were observed between localized and advanced stage of PCa for either DDE or PCB-153 exposure.

Finally, we reanalyzed the association between chlordecone exposure and PCa: the OR was 1.65 (95% CI: 1.09, 2.48;  $p_{\text{trend}} = 0.01$ ) for men in the highest quintile compared with men in the lowest quintile (see Supplemental Material, Table S6). Comparable results were observed if DDE or PCB-153 concentrations were included in the full model (OR = 1.64; 95% CI: 1.09, 2.47;  $p_{\text{trend}} = 0.01$ , and OR = 1.70; 95% CI: 1.12, 2.56;  $p_{\text{trend}} = 0.008$ , respectively) (see Supplemental Material, Table S6).

## Discussion

In our study population, the highest quintile of exposure to DDE, evaluated by determining plasma  $p,p'$ -DDE concentrations, was positively associated with incident PCa. By contrast, plasma PCB-153 was inversely associated with PCa, with significant negative associations for all quintiles above the reference level, and the strongest association with the highest quintile.

These results were obtained by studying a population with plasma concentrations consistent with the range of background environmental levels currently found in U.S. populations of similar age (Centers for Disease Control and Prevention 2009). The median value for plasma lipid-adjusted DDE (0.38  $\mu\text{g/g}$ ) and PCB-153 (0.15  $\mu\text{g/g}$ ) in our control population was, for DDE, in the same range as (0.27–0.94  $\mu\text{g/g}$ ) and, for PCB-153, slightly higher (0.04–0.09  $\mu\text{g/g}$ ) than those in control populations in other studies investigating the relationships between these pollutants, determined by blood measurement, and PCa (Aronson et al. 2010; Ritchie et al. 2003, 2005; Sawada et al. 2010; Xu et al. 2010). In the French West Indies, DDT has not been extensively used in agricultural supplies or

**Table 3.** ORs (95% CIs) of prostate cancer according to quintile of DDE and PCB-153 exposure.

| Exposure                                    | Controls (n) | Cases (n) | Crude OR (95% CI) | Adjusted OR <sup>a</sup> (95% CI) |
|---|--------------|-----------|-------------------|-----------------------------------|
| <b>DDE (<math>\mu\text{g/L}</math>)</b>     |              |           |                   |                                   |
| < 0.79                                      | 131          | 106       | 1.0 (reference)   | 1.0 (reference)                   |
| 0.79–1.62                                   | 130          | 96        | 0.91 (0.63, 1.62) | 0.96 (0.66, 1.42)                 |
| 1.63–2.89                                   | 133          | 111       | 1.03 (0.72, 1.48) | 1.05 (0.71, 1.55)                 |
| 2.90–5.18                                   | 131          | 104       | 0.98 (0.68, 1.41) | 1.02 (0.67, 1.53)                 |
| $\geq 5.19$                                 | 130          | 159       | 1.51 (1.07, 2.13) | 1.53 (1.02, 2.30)                 |
| $p_{\text{Trend}}$                          |              |           | 0.003             | 0.01                              |
| <b>PCB-153 (<math>\mu\text{g/L}</math>)</b> |              |           |                   |                                   |
| < 0.41                                      | 132          | 141       | 1.0 (reference)   | 1.0 (reference)                   |
| 0.41–0.69                                   | 132          | 109       | 0.77 (0.55, 1.09) | 0.56 (0.38, 0.83)                 |
| 0.70–1.07                                   | 134          | 135       | 0.94 (0.67, 1.32) | 0.67 (0.46, 0.99)                 |
| 1.08–1.70                                   | 131          | 110       | 0.79 (0.55, 1.11) | 0.45 (0.30, 0.63)                 |
| $\geq 1.71$                                 | 126          | 81        | 0.60 (0.42, 0.87) | 0.30 (0.19, 0.47)                 |
| $p_{\text{Trend}}$                          |              |           | 0.01              | < 0.001                           |

<sup>a</sup>For DDE: adjusted for age, waist-to-hip ratio, type 2 diabetes, alcohol, total plasma lipid concentration, and PCB-153. For PCB-153: adjusted for age, waist-to-hip ratio, Caribbean origin, past residence in Western countries, type 2 diabetes, total plasma lipid concentration, alcohol, and DDE. Missing values were imputed using a multiple imputation by chained equation (MICE) approach in five data sets.

**Table 4.** OR (95% CIs) for DDE and PCB-153, and prostate cancer by Gleason score and clinical stage.

| Exposure                                    | Controls (n) | Low grade (n) | Low-grade OR <sup>a</sup> (95% CI) | High grade (n) | High-grade OR <sup>a</sup> (95% CI) | $p$ -Value <sup>b</sup> | Localized (n) | Localized OR <sup>a</sup> (95% CI) | Advanced (n) | Advanced OR <sup>a</sup> (95% CI) | $p$ -Value <sup>c</sup> |
|---|--------------|---------------|------------------------------------|----------------|-------------------------------------|-------------------------|---------------|------------------------------------|--------------|-----------------------------------|-------------------------|
| <b>DDE (<math>\mu\text{g/L}</math>)</b>     |              |               |                                    |                |                                     |                         |               |                                    |              |                                   |                         |
| < 1.37                                      | 218          | 144           | 1.0 (reference)                    | 20             | 1.0 (reference)                     |                         | 145           | 1.0 (reference)                    | 15           | 1.0 (reference)                   |                         |
| 1.37–3.41                                   | 218          | 151           | 1.06 (0.77, 1.47)                  | 34             | 1.55 (0.85, 2.85)                   | 0.23                    | 160           | 1.11 (0.81, 1.52)                  | 23           | 1.44 (0.69, 2.98)                 | 0.50                    |
| $\geq 3.42$                                 | 219          | 167           | 1.18 (0.84, 1.65)                  | 47             | 1.92 (1.04, 3.54)                   | 0.13                    | 180           | 1.26 (0.91, 1.76)                  | 32           | 1.39 (0.66, 2.93)                 | 0.83                    |
| $p_{\text{Trend}}$                          |              |               | 0.33                               |                | 0.06                                |                         |               | 0.18                               |              | 0.55                              |                         |
| <b>PCB-153 (<math>\mu\text{g/L}</math>)</b> |              |               |                                    |                |                                     |                         |               |                                    |              |                                   |                         |
| < 0.60                                      | 218          | 183           | 1.0 (reference)                    | 28             | 1.0 (reference)                     |                         | 181           | 1.0 (reference)                    | 22           | 1.0 (reference)                   |                         |
| 0.61–1.24                                   | 216          | 174           | 0.78 (0.57, 1.06)                  | 39             | 1.11 (0.63, 1.95)                   | 0.22                    | 189           | 0.83 (0.61, 1.14)                  | 23           | 0.84 (0.42, 1.68)                 | 0.97                    |
| $\geq 1.25$                                 | 221          | 105           | 0.35 (0.25, 0.51)                  | 34             | 0.69 (0.37, 1.29)                   | 0.04                    | 115           | 0.38 (0.27, 0.55)                  | 25           | 0.64 (0.30, 1.35)                 | 0.19                    |
| $p_{\text{Trend}}$                          |              |               | < 0.001                            |                | 0.10                                |                         |               | < 0.001                            |              | 0.28                              |                         |

<sup>a</sup>For DDE: adjusted for age, waist-to-hip ratio, alcohol, type 2 diabetes, total plasma lipid concentration, and PCB-153. For PCB-153: adjusted for age, waist-to-hip ratio, Caribbean origin, past residence in Western countries, type 2 diabetes, total plasma lipid concentration, alcohol, and DDE. Missing values were imputed using a multiple imputation by chained equation (MICE) approach in five data sets. <sup>b</sup> $p$ -Value from the Wald test for heterogeneity of respective  $\beta$  coefficients between low-grade and high-grade prostate cancer. <sup>c</sup> $p$ -Value from the Wald test for heterogeneity of respective  $\beta$  coefficients between localized and advanced-stage prostate cancer.

for disease vector control. In addition, this territory has had only very limited industrial activities involving significant use or emission of PCBs. Consequently, exposure to these chemical pollutants is likely to be associated with background contamination of the food chain.

To our knowledge, this is the largest study to have investigated associations of DDE and PCBs with PCa based on biological measurements of exposure. Other strengths of this study include its population-based design, the consideration of co-exposure to other organochlorine compounds [particularly chlordane, which has been found previously to be associated with the risk of PCa (Multigner et al. 2010)], case evaluation and exposure measurement within 2 months of diagnosis and before treatment, and using multiple imputation to handle missing data.

Our study also suffers some limitations inherent in the case-control design. Factors potentially generating bias must be considered, particularly those relating to differential errors in the measurement of disease or exposure. Case identification was based on unambiguous histological criteria, and controls were also selected on the basis of strict criteria, such as normal findings on digital rectal examination and PSA in the normal range for age, taking into account the ethnic background of the population.

The use of DDT and PCBs spread worldwide around the middle of the 20th century, so the study population has probably been exposed to these chemicals or their metabolites throughout much of their lifetimes. Single determinations of plasma organochlorine concentration provide an accurate reflection of the load of this compound in the body and are commonly used as an effective way to determine the extent of chronic exposure to these chemicals. However, questions have been raised about whether a single blood determination of persistent chemicals at the time of cancer diagnosis is a reliable indicator representing lifetime exposure, particularly for breast cancer (Verner et al. 2011). Nevertheless, unlike women, men are not subject to the mobilization of fat-soluble chemicals during pregnancy or breastfeeding that can significantly alter the pollutant load of the whole body. Any previous weight loss or gain, particularly if substantial, may modify the blood concentration of these pollutants. Unfortunately, we did not collect data for our study population about the gain or loss of body weight during adulthood. To overcome, albeit only in part, this lack of information, we performed a sensitivity analysis by excluding subjects who were underweight or obese: These individuals were, perhaps, the most likely to have changed weight significantly since the beginning of adulthood.

Few studies have investigated relationships between human exposure to DDE and PCBs, determined by blood measurement, and PCa, but all were inconclusive (Aronson et al. 2010; Ritchie et al. 2003, 2005; Sawada et al. 2010; Xu et al. 2010). Nevertheless, Xu et al. (2010) reported that ORs for the second and third tertiles of DDE exposure were 2.05 (95% CI: 0.76, 5.5) and 2.64 (95% CI: 0.92, 7.57), respectively. Nonsignificant inverse associations have been reported between PCBs and PCa in a Canadian case-control study (Aronson et al. 2010) and in a Japanese nested case-control study specifically addressing advanced-stage PCa (Sawada et al. 2010). An ecological study in Eastern Slovakia reported a lower incidence of PCa in a district with extensive environmental contamination from a former PCB production site, where residents presented higher concentrations of PCBs in blood levels than in a district without any history of PCB production and where residents had low blood concentrations of PCBs (Pavuk et al. 2004).

We investigated whether exposure to DDE or PCB-153 was associated with PCa aggressiveness. Gleason score and clinical stage at diagnosis are powerful predictors of the aggressiveness of PCa. In particular, patients with high-grade Gleason scores have lower metastasis-free survival and higher PCa-specific mortality. PCB-153 exposure appeared to be negatively associated with low-grade Gleason score. Screening procedures may have introduced distortions in the associations observed between exposures of interest and cancer outcomes if fewer cases had been included in the absence of screening (Weiss 2003). In our study population, the prevalence of PSA screening among PCa cases with low-grade Gleason score was 76.7% but among PCa cases with a high-grade score, it was only 10%. Also, we found that additional adjustment for PSA screening did not change the risk estimates (data not shown). These various observations suggest that PCB-153 exposure may truly decrease the occurrence of low-grade PCa without changing the occurrence of high-grade forms. Koutros et al. (2013) have suggested that the different associations between chemical exposures (i.e., pesticides) and PCa aggressiveness may be consequences of different roles of such exposures in the prostatic carcinogenesis (for example, earlier initiation stage vs. prostate cancer progression). However, it has not been established that nonaggressive and aggressive forms of PCa are etiologically and pathogenically similar.

Finally, we found that the negative association between PCB-153 and PCa was stronger among subjects without a family history of PCa than among those with such a family history. Because the interaction terms were not strictly significant and number of

cases with a family history of PCa was very small, these results should be interpreted with caution. This result differs from those reported for various other organochlorine or pesticide exposures: Increased risks have been observed among subjects with a family history of PCa, possibly due to genetic susceptibility (Alavanja et al. 2003; Christensen et al. 2010; Lynch et al. 2009; Mahajan et al. 2006; Multigner et al. 2010). Overall, exposure to PCB-153 appears to be inversely associated with less aggressive prostate cancer and tends to be most strongly associated among subjects without a family history of PCa; such patients have a better prognosis than those with a family history (Kupelian et al. 2006).

Mainly on the basis of data from animal experiments, the International Agency for Research on Cancer (IARC) currently classifies DDT as “possibly carcinogenic to humans” and PCBs (because of their positive association with melanoma in humans) as “probably carcinogenic to humans” (IARC 1991). Both are classified as “reasonably anticipated to be human carcinogens” by the National Toxicology Program (2014). Thus, the observation from this study that PCa is positively associated with DDE and negatively associated with PCB-153 is unexpected; however, these findings may reflect differences in the hormonal properties of DDE and PCB-153 and their effects on prostate development, as discussed below.

DDE displays anti-androgenic effects *in vivo*, as assessed from changes in the weights of androgen-responsive tissues (Owens et al. 2007). These effects are probably mediated by competitive binding to the androgen receptor (AR) and/or inhibition of AR-dependent gene expression (Kelce et al. 1995, 1997). In adult healthy subjects without PCa, DDE exposure is negatively associated with serum concentration of dihydrotestosterone (Emeville et al. 2013), suggesting that DDE could also indirectly affect androgen signaling. However, DDE, like many other EDCs, has mixed actions on different members of the steroid receptor superfamily. DDE also exerts agonistic activity on estrogen receptor alpha (ER $\alpha$ ) (Li et al. 2008). ER $\alpha$  mediates adverse effects of estrogen on the prostate, including aberrant proliferation, inflammation, and malignancy (Ellem and Risbridger 2009). It is therefore difficult to predict the net effect of DDE on the prostate given potential effects on both AR and ER $\alpha$  (Carruba 2007; Ellem and Risbridger 2010).

Unlike dioxin-like PCBs, non-dioxin-like PCBs, which are the most common prevalent PCBs in the environment (McFarland and Clarke 1989), do not interact substantially with the aryl hydrocarbon receptor and may act through different pathways, such as steroid hormone signaling (Cooke et al. 2001).

Experimental studies using various animal models have shown that PCB-153—the PCB congener most commonly found in animal and human tissues, due to its high persistence and low environmental degradability (Safe 1993)—has pro-estrogenic activities (Cooke et al. 2001; Dickerson et al. 2011; Hansen 1998). However, PCBs have also been reported to be anti-estrogenic in both reporter gene and MCF-7 cell proliferation assays (Plísková et al. 2005) and to decrease ER-mediated activity in ER-CALUX bioassays (Oh et al. 2007). Thus, the actions of non-dioxin-like PCBs on ER pathways are complex and depend on the ER subtypes that are being activated or antagonized. Moreover, the non-genomic ER pathways should also be considered. In MCF-7 cells, PCB-153 induces the mitogen-activated protein kinase involved in the extracellular signal-regulated kinase (ERK) 1/2 signaling pathways (Radice et al. 2008). Several isothiocyanates from cruciferous vegetables and polyphenols from green or black tea inhibit human PCa cell proliferation (Gupta et al. 2001; Melchini et al. 2013). Interestingly, the anti-proliferative effects of these substances seem to be mediated by ERK 1/2 phosphorylation (Melchini et al. 2013; Siddiqui et al. 2004).

In summary, the modes of action of DDE and non-dioxin-like PCBs need to be investigated, particularly as involves all the various steroid receptor pathways to improve our understanding of their involvement in the proliferation or inhibition of PCa cells.

More than 20 years after the endocrine disruption concept first emerged (Colborn et al. 1993), this issue is still the subject of debate (Bergman et al. 2013; Dietrich et al. 2013; Gore et al. 2013). For instance, it has been reported that some EDCs have unexpected and potent effects at very low doses and/or do not generate the standard monotonic dose response curves seen for other types of compounds (Fagin 2012). Whether the interplay between different receptor mechanisms can generate unusual dose–response relationships and/or explains the associations we estimated for PCB-153 remains to be elucidated.

Caution is required in the interpretation of our findings. The possibility that our findings were confounded by unmeasured exposures or could be explained by reverse causality cannot be excluded. However, the possible influence, if any, of PCa on organochlorine concentrations in blood remains to be studied, and nothing is known about any underlying mechanism. Also, we cannot exclude the possibility that our findings, particularly for PCBs, may have resulted from selection bias associated with uncontrolled or unmeasured common causes of competing outcomes of PCB-related diseases and PCa (Thompson et al. 2013).

## Conclusions

In our study population of men of African descent from the French West Indies, DDE exposure was positively associated with PCa, whereas PCB-153 exposure was negatively associated with PCa. PCB-153 exposure was also inversely associated with less aggressive forms of the disease. These contrasting associations may be related to the different and sometimes multiple modes of hormonal action attributed to these two classes of pollutants. Our findings add complexity to the already controversial issue of EDCs and their suspected effects on human health. Replication of these observations in other populations, as well as mechanistic studies, is needed before any causal link can be established.

## REFERENCES

- Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, et al. 2003. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. *Am J Epidemiol* 157:800–814.
- Aronson KJ, Wilson JW, Hamel M, Diarsvitri W, Fan W, Woolcott C, et al. 2010. Plasma organochlorine levels and prostate cancer risk. *J Expo Sci Environ Epidemiol* 20:434–445.
- Bergman Å, Andersson AM, Becher G, van den Berg M, Blumberg B, Bjerregaard P, et al. 2013. Science and policy on endocrine disruptors must not be mixed: a reply to a “common sense” intervention by toxicology journal editors. *Environ Health* 12:69; doi:10.1186/1476-069X-12-69.
- Bernert JT, Turner WE, Patterson DG Jr, Needham LL. 2007. Calculation of serum “total lipid” concentrations for the adjustment of persistent organohalogen toxicant measurements in human samples. *Chemosphere* 68:824–831.
- Carruba G. 2007. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. *J Cell Biochem* 102:899–911.
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. 2012. International variation in prostate cancer incidence and mortality rates. *Eur Urol* 61:1079–1092.
- Centers for Disease Control and Prevention. 2009. Fourth Report on Human Exposure to Environmental Chemicals. Atlanta, GA:U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available: <http://www.cdc.gov/exposurereport/pdf/FourthReport.pdf> [accessed 11 November 2014].
- Christensen CH, Platz EA, Andreotti G, Blair A, Hoppin JA, Koutros S, et al. 2010. Coumaphos exposure and incident cancer among male participants in the Agricultural Health Study (AHS). *Environ Health Perspect* 118:92–96; doi:10.1289/ehp.0800446.
- Colborn T, vom Saal FS, Soto AM. 1993. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. *Environ Health Perspect* 101:378–384.
- Cooke PS, Sato T, Buchanan DL. 2001. Disruption of steroid hormone signaling by PCBs. In: *PCBs: Recent Advances in Environmental Toxicology and Health Effects* (Robertson LW, Hansen LG, eds). Lexington, KY:University Press of Kentucky, 257–263.
- Damber JE, Aus G. 2008. Prostate cancer. *Lancet* 371:1710–1721.
- Debiec C, Pomeroy PP, Dupont C, Joiris C, Comblin V, Le Boulengé E, et al. 2003. Quantitative dynamics of PCB transfer from mother to pup during lactation in UK grey seals *Halichoerus grypus*. *Mar Ecol Prog Ser* 247:237–248.
- Diamanti-Kandaraki E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. 2009. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocr Rev* 30:293–342.
- Dickerson SM, Cunningham SL, Patisaul HB, Woller MJ, Gore AC. 2011. Endocrine disruption of brain sexual differentiation by developmental PCB exposure. *Endocrinology* 152:581–594.
- Dietrich DR, Aulock Sv, Marquardt H, Blaauw B, Dekant W, Kehrer J, et al. 2013. Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles [Editorial]. *Chem Biol Interact* 205:A1–A5.
- Ellem SJ, Risbridger GP. 2009. The dual, opposing roles of estrogen in the prostate. *Ann NY Acad Sci* 1155:174–186.
- Ellem SJ, Risbridger GP. 2010. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. *J Steroid Biochem Mol Biol* 118:246–251.
- Emeville E, Giton F, Giusti A, Oliva A, Fiet J, Thomé JP, et al. 2013. Persistent organochlorine pollutants with endocrine activity and blood steroid hormone levels in middle-aged men. *PLoS One* 8:e66460; doi:10.1371/journal.pone.0066460.
- Fagin D. Toxicology: the learning curve. 2012. *Nature* 490:462–465.
- Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, et al. 2013. Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al. [Letter]. *Endocrinology* 154:3957–3960.
- Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. 2001. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. *Proc Natl Acad Sci USA* 98:10350–10355.
- Hansen LG. 1998. Stepping backward to improve assessment of PCB congener toxicities. *Environ Health Perspect* 106(suppl 1):171–189.
- Hsing AW, Chokkalingam AP. 2006. Prostate cancer epidemiology. *Front Biosci* 11:1388–1413.
- IARC (International Agency for Research on Cancer). 1991. Occupational exposures in insecticide application, and some pesticides. IARC Monogr Eval Carcinog Risk Hum 53:179–250.
- Kelce WR, Lambright CR, Gray LE Jr, Roberts KP. 1997. Vinclozolin and *p,p'*-DDE alter androgen-dependent gene expression: *in vivo* confirmation of an androgen receptor-mediated mechanism. *Toxicol Appl Pharmacol* 142:192–200.
- Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. 1995. Persistent DDT metabolite *p,p'*-DDE is a potent androgen antagonist. *Nature* 376:581–585.
- Koutros S, Beane Freeman LE, Lubin JH, Heltshe SL, Andreotti G, Barry KH, et al. 2013. Risk of total and aggressive prostate cancer and pesticide use in the Agricultural Health Study. *Am J Epidemiol* 177:59–74.
- Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. 2006. Aggressiveness of Familial Prostate Cancer. *J Clin Oncol* 24:3445–3450.
- Li J, Li N, Ma M, Giesy JP, Wang Z. 2008. *In vitro* profiling of the endocrine disrupting potency of organochlorine pesticides. *Toxicol Lett* 183:65–71.
- Little RJA, Rubin DB. 1987. Statistical Analysis with Missing Data. New York:John Wiley & Sons.
- Lynch SM, Mahajan R, Beane Freeman LE, Hoppin JA, Alavanja MC. 2009. Cancer incidence among pesticide applicators exposed to butylate in the Agricultural Health Study (AHS). *Environ Res* 109:860–868.

- Mahajan R, Bonner MR, Hoppin JA, Alavanja MC. 2006. Phorate exposure and incidence of cancer in the Agricultural Health Study. *Environ Health Perspect* 114:1205–1209; doi:10.1289/ehp.8911.
- McFarland VA, Clarke JU. 1989. Environmental occurrence, abundance, and potential toxicity of polychlorinated biphenyl congeners: considerations for a congener-specific analysis. *Environ Health Perspect* 81:225–239.
- Melchini A, Traka MH, Catania S, Miceli N, Taviano MF, Maimone P, et al. 2013. Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells. *Nutr Cancer* 65:132–138.
- Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. 1996. Age-specific reference ranges for prostate-specific antigen in black men. *N Engl J Med* 335:304–310.
- Multigner L, Ndong JR, Giusti A, Romana M, Delacroix-Maillard H, Cordier S, et al. 2010. Chlordecone exposure and risk of prostate cancer. *J Clin Oncol* 28:3457–3462.
- National Toxicology Program. 2014. Report on Carcinogens, 13th Report on Carcinogens (RoC). Research Triangle Park, NC:U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. Available: <http://ntp.niehs.nih.gov/go/roc13> [accessed 11 November 2014].
- Oh SM, Ryu BT, Lee SK, Chung KH. 2007. Antiestrogenic potentials of ortho-PCB congeners by single or complex exposure. *Arch Pharm Res* 30:199–209.
- Owens W, Gray LE, Zeiger E, Walker M, Yamasaki K, Ashby J, et al. 2007. The OECD program to validate the rat Hershberger bioassay to screen compounds for *in vivo* androgen and antiandrogen responses: phase 2 dose-response studies. *Environ Health Perspect* 115:671–678; doi:10.1289/ehp.9666.
- Pavuk M, Cerhan JR, Lynch CF, Schecter A, Petrik J, Chovanova J, et al. 2004. Environmental exposure to PCBs and cancer incidence in eastern Slovakia. *Chemosphere* 54:1509–1520.
- Plísková M, Vondráček J, Canton RF, Nera J, Kocan A, Petrik J, et al. 2005. Impact of polychlorinated biphenyls contamination on estrogenic activity in human male serum. *Environ Health Perspect* 113:1277–1284; doi:10.1289/ehp.7745.
- Porta M, Jarrod M, López T, Pumarega J, Puigdomènech E, Marco E, et al. 2009. Correcting serum concentrations of organochlorine compounds by lipids: alternatives to the organochlorine/total lipids ratio. *Environ Int* 35:1080–1085.
- Prins GS. 2008. Endocrine disruptors and prostate cancer risk. *Endocr Relat Cancer* 15:649–656.
- Radice S, Chiesara E, Fucile S, Marabini L. 2008. Different effects of PCB101, PCB118, PCB138 and PCB153 alone or mixed in MCF-7 breast cancer cells. *Food Chem Toxicol* 46:2561–2567.
- Ritchie JM, Vial SL, Fuortes LJ, Guo H, Reedy VE, Smith EM. 2003. Organochlorines and risk of prostate cancer. *J Occup Environ Med* 45:692–702.
- Ritchie JM, Vial SL, Fuortes LJ, Robertson LW, Guo H, Reedy VE, et al. 2005. Comparison of proposed frameworks for grouping polychlorinated biphenyl congener data applied to a case-control pilot study of prostate cancer. *Environ Res* 98:104–113.
- Rubin DB. 1987. Multiple Imputation for Nonresponse in Surveys. New York:John Wiley & Sons, Inc.
- Safe S. 1993. Toxicology, structure-function relationship, and human and environmental health impacts of polychlorinated biphenyls: progress and problems. *Environ Health Perspect* 100:259–268.
- Sawada N, Iwasaki M, Inoue M, Itoh H, Sasazuki S, Yamaji T, et al. 2010. Plasma organochlorines and subsequent risk of prostate cancer in Japanese men: a nested case-control study. *Environ Health Perspect* 118:659–665; doi:10.1289/ehp.0901214.
- Seaman SR, Bartlett JW, White JR. 2012. Multiple imputation of missing covariates with non-linear effects and interactions: an evaluation of statistical methods. *BMC Med Res Methodol* 12:46; doi:10.1186/1471-2288-12-46.
- Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H. 2004. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. *J Cell Biochem* 91:232–242.
- Soto AM, Sonnenschein C. 2010. Environmental causes of cancer: endocrine disruptors as carcinogens. *Nat Rev Endocrinol* 6:363–370.
- Thompson CA, Zhang ZF, Arah OA. 2013. Competing risk bias to explain the inverse relationship between smoking and malignant melanoma. *Eur J Epidemiol* 28:557–567.
- Van Buuren S, Boshuizen HC, Knook DL. 1999. Multiple imputation of missing blood pressure covariates in survival analysis. *Stat Med* 18:681–694.
- Verner MA, Bachelet D, McDougall R, Charbonneau M, Guénel P, Haddad S. 2011. A case study addressing the reliability of polychlorinated biphenyl levels measured at the time of breast cancer diagnosis in representing early-life exposure. *Cancer Epidemiol Biomarkers Prev* 20:281–286.
- Weiss NS. 2003. Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. *Am J Epidemiol* 157:957–961.
- White IR, Royston P, Wood AM. 2009. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 30:377–399.
- World Health Organization. 2013. State of the Science of Endocrine Disrupting Chemicals—2012 (Bergman Å, Heindel JJ, Jobling S, Kidd KA, Zoeller RT, eds). Available: [http://unep.org/pdf/9789241505031\\_eng.pdf](http://unep.org/pdf/9789241505031_eng.pdf) [accessed 11 November 2014].
- Xu X, Dailey AB, Talbott EO, Ilacqua VA, Kearney G, Asal NR. 2010. Associations of serum concentrations of organochlorine pesticides with breast cancer and prostate cancer in U.S. adults. *Environ Health Perspect* 118:60–66; doi:10.1289/ehp.0900919.



**Supplemental Material**

**Associations of Plasma Concentrations of  
Dichlorodiphenyldichloroethylene and Polychlorinated Biphenyls  
with Prostate Cancer: A Case–Control Study in Guadeloupe  
(French West Indies)**

Elise Emeville, Arnaud Giusti, Xavier Coumoul, Jean-Pierre Thomé, Pascal Blanchet, and Luc  
Multigner

**Table S1.** Spearman's rank correlation analysis of the relationship between concentrations of frequently detected (Limit of detection >80 %) pollutants in plasma samples from controls subjects and cases patients.

| <b>Controls subjects (n = 655)</b> | <b>PCB138</b>             | <b>PCB153</b>             | <b>PCB180</b>             | <b>Chlordecone</b>         |
|------------------------------------|---------------------------|---------------------------|---------------------------|----------------------------|
| DDE                                | $r = 0.48$<br>$P < 0.001$ | $r = 0.38$<br>$P < 0.001$ | $r = 0.26$<br>$P < 0.001$ | $r = 0.05$<br>$P = 0.18$   |
| PCB138                             | -                         | $r = 0.88$<br>$P < 0.001$ | $r = 0.84$<br>$P < 0.001$ | $r = 0.10$<br>$P = 0.007$  |
| PCB153                             | -                         | -                         | $r = 0.81$<br>$P < 0.001$ | $r = 0.07$<br>$P = 0.06$   |
| PCB180                             | -                         | -                         | -                         | $r = 0.09$<br>$P = 0.002$  |
| <b>Cases patients (n = 576)</b>    |                           |                           |                           |                            |
| DDE                                | $r = 0.50$<br>$P < 0.001$ | $r = 0.44$<br>$P < 0.001$ | $r = 0.33$<br>$P < 0.001$ | $r = 0.04$<br>$P = 0.29$   |
| PCB138                             | -                         | $r = 0.84$<br>$P < 0.001$ | $r = 0.82$<br>$P < 0.001$ | $r = 0.12$<br>$P = 0.003$  |
| PCB153                             | -                         | -                         | $r = 0.76$<br>$P < 0.001$ | $r = 0.07$<br>$P = 0.09$   |
| PCB180                             | -                         | -                         | -                         | $r = 0.14$<br>$P = 0.0008$ |

**Table S2.** Geometric means of DDE and PCB153 plasma concentrations according to study population characteristics.

| <b>Characteristic</b>                      | <b>DDE<br/>Geometric means<br/>(CI 95%)</b> | <b>P value<sup>a</sup></b> | <b>PCB153<br/>Geometric means<br/>(CI 95%)</b> | <b>P-value<sup>a</sup></b> |
|--|---|----------------------------|--|----------------------------|
| <b>Caribbean origin</b>                    |   | 0.42                       |  | <0.001                     |
| French West Indies                         | 1.96 (1.78, 2.15)                           |                            | 0.78 (0.73, 0.83)                              |                            |
| Haiti or Dominica                          | 1.71 (1.19, 2.45)                           |                            | 0.28 (0.22, 0.35)                              |                            |
| <b>Education</b>                           |   | 0.59                       |  | 0.61                       |
| Primary                                    | 1.84 (1.62, 2.09)                           |                            | 0.78 (0.64, 0.95)                              |                            |
| Secondary                                  | 2.00 (1.67, 2.40)                           |                            | 0.72 (0.63, 0.81)                              |                            |
| High school and higher                     | 2.02 (1.62, 2.68)                           |                            | 0.72 (0.66, 0.78)                              |                            |
| <b>Body mass index (kg/m<sup>2</sup>)</b>  |   | <0.001                     |  | 0.03                       |
| <25  | 1.59 (1.38, 1.84)                           |                            | 0.68 (0.62, 0.75)                              |                            |
| 25 - <30                                   | 2.06 (1.78, 2.40)                           |                            | 0.79 (0.72, 0.88)                              |                            |
| >30  | 3.02 (2.27, 4.02)                           |                            | 0.73 (0.60, 0.89)                              |                            |
| <b>Waist-to-hip-ratio</b>                  |   | <0.001                     |  | 0.01                       |
| <0.95                                      | 1.66 (1.47, 1.88)                           |                            | 0.70 (0.64, 0.77)                              |                            |
| >0.95                                      | 2.50 (2.12, 2.95)                           |                            | 0.83 (0.74, 0.93)                              |                            |
| <b>Smoking</b>                             |   | 0.35                       |  | 0.01                       |
| Never                                      | 1.89 (1.68, 2.12)                           |                            | 0.69 (0.64, 0.75)                              |                            |
| Former or current                          | 2.04 (1.76, 2.36)                           |                            | 0.80 (0.73, 0.89)                              |                            |
| <b>Alcohol consumption</b>                 |   | 0.01                       |  | 0.009                      |
| Never                                      | 1.53 (1.21, 1.92)                           |                            | 0.62 (0.52, 0.72)                              |                            |
| Former or current                          | 2.02 (1.83, 2.23)                           |                            | 0.75 (0.70, 0.81)                              |                            |
| <b>Type 2 diabetes</b>                     |   | <0.001                     |  | 0.02                       |
| No   | 1.81 (1.64, 1.99)                           |                            | 0.72 (0.67, 0.77)                              |                            |
| Yes  | 2.71 (2.15, 3.42)                           |                            | 0.86 (0.73, 1.01)                              |                            |
| <b>PSA screening history</b>               |   | 0.30                       |  | 0.44                       |
| No   | 1.83 (1.69, 2.10)                           |                            | 0.72 (0.67, 0.78)                              |                            |
| Yes  | 2.06 (1.75, 2.43)                           |                            | 0.76 (0.68, 0.85)                              |                            |
| <b>Family history of prostate cancer</b>   |   | 0.66                       |  | 0.36                       |
| No   | 1.95 (1.73, 2.20)                           |                            | 0.75 (0.69, 0.81)                              |                            |
| Yes  | 1.94 (1.53, 2.46)                           |                            | 0.67 (0.57, 0.79)                              |                            |
| Do not know                                | 1.75 (1.36, 2.26)                           |                            | 0.73 (0.61, 0.87)                              |                            |
| <b>Past residence in Western countries</b> |   | 0.71                       |  | <0.001                     |
| No   | 1.92 (1.67, 2.37)                           |                            | 0.65 (0.61, 0.70)                              |                            |
| Yes  | 1.99 (1.73, 2.14)                           |                            | 1.00 (0.89, 1.13)                              |                            |

<sup>a</sup>P-values were calculated using ANOVA tests (two-sided).

**Table S3.** Sensitivity analysis of the association between DDE exposure and prostate cancer.

|  | DDE exposure<br><0.79 µg/L | DDE exposure<br>0.79-1.62 µg/L | DDE exposure<br>1.63-2.89 µg/L | DDE exposure<br>2.90-5.18 µg/L | DDE exposure<br>>5.19 µg/L | P-Trend |
|--|----------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------|---------|
| <b>Controls subjects/cases patients (n)</b>  | 131/106                    | 130/96                         | 133/111                        | 131/104                        | 130/159                    |         |
| <b>Adjusted<sup>a</sup></b><br>OR (95% CI)   | 1.0                        | 0.96 (0.66, 1.42)              | 1.05 (0.71, 1.55)              | 1.02 (0.67, 1.53)              | 1.53 (1.02, 2.30)          | 0.01    |
| <b>Adjusted<sup>b</sup></b><br>OR (95% CI)   | 1.0                        | 1.00 (0.63, 1.56)              | 1.05 (0.66, 1.64)              | 1.01 (0.63, 1.62)              | 1.64 (1.04, 2.59)          | 0.007   |
| <b>Adjusted<sup>c</sup></b><br>OR (95% CI)   | 1.0                        | 1.04 (0.65, 1.63)              | 1.03 (0.64, 1.64)              | 0.99 (0.61, 1.61)              | 1.73 (1.08, 2.78)          | 0.006   |
| <b>Adjusted<sup>a</sup> including BMI</b><br>OR (95% CI)   | 1.0                        | 0.96 (0.65, 1.43)              | 1.05 (0.70, 1.55)              | 1.01 (0.67, 1.53)              | 1.54 (1.03, 2.31)          | 0.01    |
| <b>Adjusted<sup>a</sup> including family history of prostate cancer</b><br>OR (95% CI)                         | 1.0                        | 1.00 (0.66, 1.51)              | 1.08 (0.72, 1.62)              | 1.01 (0.66, 1.55)              | 1.64 (1.08, 2.48)          | 0.006   |
| <b>Adjusted<sup>a</sup> including PSA screening history</b><br>OR (95% CI)                                     | 1.0                        | 1.00 (0.70, 1.64)              | 1.06 (0.69, 1.64)              | 1.05 (0.67, 1.65)              | 1.55 (1.00, 2.41)          | 0.03    |
| <b>Adjusted<sup>a</sup> including chlordecone</b><br>OR (95% CI)   | 1.0                        | 0.92 (0.62, 1.37)              | 1.04 (0.70, 1.54)              | 1.03 (0.68, 1.56)              | 1.51 (1.01, 2.27)          | 0.01    |
| <b>Adjusted<sup>a,d</sup> excluding subjects with BMI &lt;18.5 and subjects with BMI &gt;30</b><br>OR (95% CI) | 1.0                        | 1.00 (0.66, 1.54)              | 0.99 (0.65, 1.53)              | 1.07 (0.70, 1.66)              | 1.43 (0.93, 2.20)          | 0.04    |

<sup>a</sup>Adjusted for age, waist-to-hip-ratio, type 2 diabetes, alcohol, total plasma lipid concentration and PCB153, with missing values imputed using a Multiple Imputation by Chained Equation (MICE) approach in five data sets. <sup>b</sup>Adjusted for age, waist-to-hip-ratio, type 2 diabetes, alcohol, total plasma lipid concentration and PCB153, with missing value indicator categories. <sup>c</sup>Adjusted for age, waist-to-hip-ratio, type 2 diabetes, alcohol, total plasma lipid concentration and PCB153, and restricted to controls and cases with complete datasets. No. of controls/cases were, 125/64, 126/62, 126/63, 125/59, and 120/101 for quintiles 1 to 5 respectively. <sup>d</sup>No. of controls/cases were, 121/95, 108/81, 124/ 87, 110/88, and 110/120 for quintiles 1 to 5 respectively.



**Table S4.** Sensitivity analysis of the association between PCB153 exposure and prostate cancer.

|  | <b>PCB153 exposure<br/>&lt;0.41 µg/L</b> | <b>PCB153 exposure<br/>0.41-0.69 µg/L</b> | <b>PCB153 exposure<br/>0.70-1.07 µg/L</b> | <b>PCB153 exposure<br/>1.08-1.70 µg/L</b> | <b>PCB153 exposure<br/>&gt;1.71 µg/L</b> | <b>P-Trend</b> |
|--|--|---|---|---|--|----------------|
| <b>Controls subjects/cases patients (n)</b>  | 132/141                                  | 132/109                                   | 134/135                                   | 131/110                                   | 130/159                                  |                |
| <b>Adjusted<sup>a</sup></b><br>OR (95% CI)   | 1.0                                      | 0.56 (0.38, 0.83)                         | 0.67 (0.46, 0.99)                         | 0.45 (0.30, 0.63)                         | 0.30 (0.19, 0.47)                        | <0.001         |
| <b>Adjusted<sup>b</sup></b><br>OR (95% CI)   | 1.0                                      | 0.65 (0.42, 1.01)                         | 0.68 (0.43, 1.05)                         | 0.43 (0.27, 0.70)                         | 0.31 (0.18, 0.52)                        | <0.001         |
| <b>Adjusted<sup>c</sup></b><br>OR (95% CI)   | 1.0                                      | 0.64 (0.44, 1.09)                         | 0.74 (0.47, 1.65)                         | 0.40 (0.25, 0.66)                         | 0.29 (0.17, 0.50)                        | <0.001         |
| <b>Adjusted<sup>a</sup> including BMI</b><br>OR (95% CI)   | 1.0                                      | 0.56 (0.38, 0.83)                         | 0.67 (0.46, 0.99)                         | 0.45 (0.30, 0.69)                         | 0.30 (0.19, 0.47)                        | <0.001         |
| <b>Adjusted<sup>a</sup> including family history of<br/>prostate cancer</b><br>OR (95% CI)                         | 1.0                                      | 0.60 (0.40, 0.89)                         | 0.67 (0.45, 1.00)                         | 0.48 (0.31, 0.73)                         | 0.31 (0.19, 0.49)                        | <0.001         |
| <b>Adjusted<sup>a</sup> including PSA screening<br/>history</b><br>OR (95% CI)                                     | 1.0                                      | 0.60 (0.40, 0.92)                         | 0.68 (0.45, 1.03)                         | 0.42 (0.26, 0.65)                         | 0.31 (0.19, 0.51)                        | <0.001         |
| <b>Adjusted<sup>a</sup> including chlordecone</b><br>OR (95% CI)   | 1.0                                      | 0.54 (0.37, 0.80)                         | 0.64 (0.43, 0.65)                         | 0.43 (0.28, 0.65)                         | 0.28 (0.18, 0.45)                        | <0.001         |
| <b>Adjusted<sup>a,d</sup> excluding subjects with BMI<br/>&lt;18.5 and subjects with BMI &gt;30</b><br>OR (95% CI) | 1.0                                      | 0.65 (0.43, 1.00)                         | 0.73 (0.47, 1.11)                         | 0.54 (0.36, 0.86)                         | 0.31 (0.18, 0.51)                        | <0.001         |

<sup>a</sup>Adjusted for age, waist-to-hip-ratio, diabetes type 2, Caribbean origin, past residence in western countries, total plasma lipid concentration and DDE, with missing values imputed using a Multiple Imputation by Chained Equation (MICE) approach in five data sets. <sup>b</sup>Adjusted for age, waist-to-hip-ratio, diabetes type 2, Caribbean origin, past residence in western countries, total plasma lipid concentration and DDE, with missing value indicator categories. <sup>c</sup>Adjusted for age, waist-to-hip-ratio, diabetes type 2, Caribbean origin, past residence in western countries, total plasma lipid concentration and DDE, and restricted to controls and cases with complete datasets for. No. of controls/cases were 119/129, 111 /94, 123/118, 111/ 101, and 113/73 for quintiles 1 to 5 respectively. <sup>d</sup>No. of controls/cases were, 115/110, 109/90, 117/108, 108/97, and 112/66 for quintiles 1 to 5 respectively.

**Table S5.** PCB153 exposure and prostate cancer according to family history of prostate cancer.

| PCB153 exposure (µg/L) | No family history<br>No. controls | No family history<br>No. cases | No family history:<br>Adjusted<br>OR <sup>a</sup> (95% CI) | With family history<br>No. controls | With family history<br>No. cases | With family history:<br>Adjusted<br>OR <sup>a</sup> (95% CI) | P-Interaction |
|------------------------|-----------------------------------|--------------------------------|--|-------------------------------------|----------------------------------|--|---------------|
| <0.41                  | 87                                | 47                             | 1.0  | 17                                  | 22                               | 1.0  |               |
| 0.41-0.69              | 99                                | 38                             | 0.42 (0.23, 0.78)  | 12                                  | 14                               | 0.98 (0.29, 3.32)  | 0.31          |
| 0.70-1.07              | 97                                | 41                             | 0.47 (0.23, 0.80)  | 14                                  | 23                               | 1.91 (0.60, 6.10)  | 0.07          |
| 1.08-1.70              | 99                                | 36                             | 0.30 (0.16, 0.59)  | 7                                   | 15                               | 1.28 (0.33, 5.03)  | 0.10          |
| >1.71                  | 96                                | 28                             | 0.20 (0.10, 0.41)  | 10                                  | 14                               | 0.84 (0.20, 3.40)  | 0.09          |
| <b>P-Trend</b>         |                                   |                                | <0.001   |                                     |                                  | 0.88   |               |

<sup>a</sup>Adjusted for age, waist-to-hip-ratio, Caribbean origin, past residence in western countries, type 2 diabetes, total plasma lipid concentration, alcohol and DDE, and restricted to controls and cases with complete datasets for.

**Table S6.** ORs (95% CIs) of prostate cancer according to quintile of chlordecone.

|  | <b>Chlordecone<br/>exposure<br/>&lt;0.13 µg/L</b> | <b>Chlordecone<br/>exposure<br/>0.13-0.30 µg/L</b> | <b>Chlordecone<br/>exposure<br/>0.31-0.51 µg/L</b> | <b>Chlordecone<br/>exposure<br/>0.52-1.02 µg/L</b> | <b>Chlordecone<br/>exposure<br/>≥1.03 µg/L</b> | <b>P-Trend</b> |
|--|---|--|--|--|--|----------------|
| <b>Controls subjects/cases patients (n)</b>                  | 132/113   | 128/85   | 131/127  | 134/121  | 130/130  |                |
| <b>Adjusted<sup>a</sup><br/>OR (95% CI)</b>                  | 1.0   | 1.00 (0.65, 1.54)                                  | 1.47 (0.98, 2.21)                                  | 1.41 (0.94, 2.13)                                  | 1.65 (1.09, 2.48)                              | 0.01           |
| <b>Adjusted<sup>a</sup> including DDE<br/>OR (95% CI)</b>    | 1.0   | 1.01 (0.66, 1.56)                                  | 1.48 (0.99, 2.22)                                  | 1.41 (0.93, 2.12)                                  | 1.64 (1.09, 2.47)                              | 0.01           |
| <b>Adjusted<sup>a</sup> including PCB153<br/>OR (95% CI)</b> | 1.0   | 0.98 (0.64, 1.52)                                  | 1.51 (1.01, 2.27)                                  | 1.45 (0.96, 2.27)                                  | 1.70 (1.12, 2.56)                              | 0.008          |

<sup>a</sup>Adjusted for age, waist-to-hip-ratio, PSA screening history, and total plasma lipid concentration. Missing values were imputed using a Multiple Imputation by Chained Equation (MICE) approach in five datasets.